Type 2 Diabetes

Better Therapeutics plans to go public through SPAC merger 

  • by

Digital health startup Better Therapeutics plans to go public through a SPAC merger that would value it at $187 million. The company is currently running a pivotal study to see if its app-based program could be used as a treatment for type 2 diabetes. 

Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes

  • by

Shots: The P-III SURPASS-2 trial involves assessing Tirzepatide (5/10/15mg) vs Semaglutide (1mg) in 1,879 patients in a ratio (1:1:1:1) with T2D inadequately controlled with ≥1500 mg/day metformin alone for 40wks. Results: A1C reduction: (-2.09% /-2.37%/-2.46% vs- 1.86%); Weight reduction: (-7.8/-10.3/-12.4kg vs -6.2 kg); patients achieving… Read More »Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes

Lilly Reports Results of Tirzepatide in P-lll SURPASS-3 and 5 Trials for Type-2 Diabetes

  • by

Shots: The P-lll SURPASS-3 study involves assessing Tirzepatide (5/10/15 mg) vs titrated insulin degludec in 1444 participants in a ratio (1:1:1:1) with T2D treated with metformin with or without an SGLT-2 inhibitor for 52wks. The P-lll SURPASS-5 study involves assessing Tirzepatide (5/10/15 mg) vs PBO… Read More »Lilly Reports Results of Tirzepatide in P-lll SURPASS-3 and 5 Trials for Type-2 Diabetes

Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes

  • by

Shots: The P-lll SURPASS-1 study involves assessing Tirzepatide as monothx. (5/10/15 mg) vs PBO in 478 patients in the ratio of (1:1:1:1) with T2D inadequately controlled with diet and exercise alone Results: A1C reduction: (-1.75% /-1.71%/-1.69% vs- 0.09%); Weight reduction: 6.3/7.0/7.8kg vs 1.0 kg; percentage… Read More »Lilly Reports Results of Tirzepatide in P-lll SURPASS-1 Monotherapy Trial for Type-2 Diabetes

Bayer’s Finerenone Demonstrates Positive Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

  • by

Shots: The P-III FIDELIO-DKD study in CKD and T2D enrolled over 13,000 patients with early kidney damage and more advanced stages of kidney disease. The data were presented at the ASN Kidney Week 2020 and published in the NEJM based on which Bayer submitted finerenone… Read More »Bayer’s Finerenone Demonstrates Positive Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

Intermountain Adds Omada’s Diabetes Prevention Program to At-Risk Patients

  • by

What You Should Know: – Omada’s diabetes prevention program will be available to Intermountain’s at-risk patient population as part of a limited engagement in 2020 and 2021. – Omada’s diabetes prevention program is personalized to meet each participant’s unique needs as they evolve, ranging from… Read More »Intermountain Adds Omada’s Diabetes Prevention Program to At-Risk Patients